Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Avalon Globocare Corp (AVCO)

Organization & Developments: Avalon Globocare

Parents

Avalon Globocare Corp (AVCO)
Pioneers: Triple Helix: New Business Models_Open Innovation, Virtual Organizations, Royalty Aggregators, Etc.

2018: Avalon GloboCare Teams Up with Weill Cornell Medicine to Co-develop Standardization of cGMP-Grade Exosome Isolation and Application of Tissue-Specific Exosomes
2018: Avalon GloboCare Teams up with Weill Cornell Medicine to Establish Joint Translational Research Initiative in Stem Cell Technology and Regenerative Medicine
2019: Avalon GloboCare +22% on partnership with GE Healthcare_seekingalpha.com
2019: Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines
2019: Avalon GloboCare Partners with MIT to Develop Innovative AI-Enhanced Protein Design Technology in Cellular Therapy Nasdaq:AVCO
2019: Avalon GloboCare: A Trifecta Biotech_seekingalpha.com
2019: Avalon will initiate research and development with MIT professors Robert S. Langer and Shuguang Zhang to design the next generation of therapeutics for Cytokine Release Syndrome, T-cell leukemia, as well as novel methodology to re-engineer immune cells for cellular immunotherapy.
2019: Avalon: Poised For Market Conquest_seekingalpha.com
2019: Entered into a sponsored research and licensing agreement with Massachusetts Institute of Technology (MIT) to generate novel therapeutic targets for cellular therapy using artificial intelligence (AI) enhanced protein design “QTY Code” technology.
2019: IBI Research On Avalon GloboCare: Hitting Mega Rallies_seekingalpha.com
A leading global developer of cell-based technologies and therapeutics